https://stage--stage-takhzyro--onetakeda.aem.page/hcp/safety-profile/fragments/safety-header
Style
section-no-margin, section-no-padding

HELP STUDY

HELP OLE STUDY

REAL WORLD EMPOWER STUDY

SPRING STUDY

Style
Inner-content-contained, section-no-top-margin, section-no-bottom-margin, flex-stretch, section-no-top-padding, section-no-bottom-padding, pink-tertiary-btn

HELP safety results

Safety profile established in the largest pivotal trial prevention study in HAE1,3–5

Most common adverse reactions (≥10%) observed in the pivotal trial1,2*
TAKHZYRO every 2 weeks
(n=27)
TAKHZYRO every 4 weeks
(n=29)
Placebo
(n=41)

Injection site reactions†

  • Pain
  • Erythema
  • Bruising

56%

52%

7%

4%

45%

31%

7%

7%

34%

29%

2%

0%

Upper respiratory infection‡
44%
31%
32%
Headache§
33%
21%
22%
RashII
4%
10%
5%
Dizziness
4%
10%
0%
Diarrhea
4%
0%
5%
Myalgia
11%
0%
0%

*≥10% in any TAKHZYRO group that also occurred at a higher rate than placebo group.1
†Additional injection site reactions included hematoma, hemorrhage, pruritus, swelling, induration, paresthesia reaction, warmth, edema, and rash.1
‡Includes upper respiratory infection, viral upper respiratory infection.1
§Includes headache, tension headache, sinus headache.1
IIIncludes rash, rash maculopapular, rash erythematous.1

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.1

No incidence of anaphylaxis in the pivotal trial.1

Injection site reactions were the most common adverse reactions (ARs).1

Style
Inner-content-contained, section-no-top-margin, section-no-bottom-margin, section-no-bottom-padding, section-footnote, h4-magenta, section-safety-tabs

Explore more safety information

HELP OLE STUDY

REAL WORLD EMPOWER STUDY

SPRING STUDY

Style
Inner-content-contained, section-no-bottom-margin, flex-stretch, section-no-bottom-padding, section-no-top-padding
https://stage--stage-takhzyro--onetakeda.aem.page/hcp/safety-profile/fragments/offers-info
Style
section-no-top-padding, section-no-bottom-margin, section-no-bottom-padding, background-lavender-light, inner-content-contained

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2025. 2. Banerji A, Riedl MA, Bernstein JA, et al. JAMA. 2018;320(20):2108-2121. doi:10.1001/jama.2018.16773 3. Cinryze. Prescribing information. Takeda Pharmaceuticals USA, Inc; 2023. 4. Haegarda. Prescribing information. CSL Behring LLC; 2022. 5. Orladeyo. Prescribing information. BioCryst Pharmaceuticals, Inc; 2022.

Style
Inner-content-contained, section-references, section-no-top-margin, section-no-bottom-margin
https://main--takeda-eds-sites-takhzyro--onetakeda.hlx.page/hcp/fragments/isi
Style
Inner-content-contained, section-no-margin
id
important-safety-information